MX354187B - Composicion farmaceutica combinada y metodos para el tratamiento de los trastornos del sistema genitourinario. - Google Patents

Composicion farmaceutica combinada y metodos para el tratamiento de los trastornos del sistema genitourinario.

Info

Publication number
MX354187B
MX354187B MX2013000547A MX2013000547A MX354187B MX 354187 B MX354187 B MX 354187B MX 2013000547 A MX2013000547 A MX 2013000547A MX 2013000547 A MX2013000547 A MX 2013000547A MX 354187 B MX354187 B MX 354187B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
methods
antibody
activated
system disorders
Prior art date
Application number
MX2013000547A
Other languages
English (en)
Other versions
MX2013000547A (es
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of MX2013000547A publication Critical patent/MX2013000547A/es
Publication of MX354187B publication Critical patent/MX354187B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica homeopática que comprende a) una forma activada potenciada de un anticuerpo contra el antígeno prostático específico, y b) una forma activada potenciada de un anticuerpo contra la NO sintasa endotelial, en donde dicha forma activada potenciada de un anticuerpo contra el antígeno prostático específico y dicha forma activa potenciada de un anticuerpo contra la NO sintasa endotelial están en la forma de una mezcla de diluciones homeopáticas C12, C30 y C200.
MX2013000547A 2010-07-15 2011-07-15 Composicion farmaceutica combinada y metodos para el tratamiento de los trastornos del sistema genitourinario. MX354187B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
PCT/IB2011/002417 WO2012007849A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders

Publications (2)

Publication Number Publication Date
MX2013000547A MX2013000547A (es) 2014-04-14
MX354187B true MX354187B (es) 2018-02-16

Family

ID=44899158

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000547A MX354187B (es) 2010-07-15 2011-07-15 Composicion farmaceutica combinada y metodos para el tratamiento de los trastornos del sistema genitourinario.

Country Status (17)

Country Link
US (1) US20130064860A1 (es)
EP (1) EP2593483A2 (es)
JP (3) JP2013538791A (es)
CN (1) CN103282384A (es)
AU (1) AU2011278042B2 (es)
CA (1) CA2805094A1 (es)
DE (1) DE112011102350T5 (es)
EA (1) EA029860B1 (es)
ES (1) ES2425314R1 (es)
FR (1) FR2962655A1 (es)
GB (1) GB2495885B (es)
IT (1) ITTO20110631A1 (es)
MX (1) MX354187B (es)
MY (1) MY165267A (es)
NZ (1) NZ606775A (es)
SG (2) SG10201505564VA (es)
WO (1) WO2012007849A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EA030566B1 (ru) 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
DE112011102362T5 (de) 2010-07-15 2013-04-25 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
ITTO20110632A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare il disturbo da deficit di attenzione e iperattivita'
CA2805978C (en) 2010-07-21 2016-06-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
CN110755599A (zh) * 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
UA76641C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
EP1796480B1 (en) * 2004-09-03 2011-11-09 Chr. Hansen A/S Fermented milk proteins comprising receptor ligand and uses thereof
NZ571673A (en) * 2006-04-04 2011-08-26 Dong A Pharm Co Ltd A pyrazolopyrimidinone derivative for the prevention and treatment of prostatic hyperplasia
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
JP2009542800A (ja) * 2006-07-13 2009-12-03 マゼンス インコーポレイテッド 金属の吸収を促進する金属−酸性アミノ酸キレートを含有する組成物
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
EA030542B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция

Also Published As

Publication number Publication date
EA029860B1 (ru) 2018-05-31
DE112011102350T5 (de) 2013-04-18
JP2013538791A (ja) 2013-10-17
WO2012007849A2 (en) 2012-01-19
EA201300129A1 (ru) 2013-12-30
AU2011278042A1 (en) 2013-03-07
GB2495885B (en) 2017-11-22
ITTO20110631A1 (it) 2012-01-16
JP2016199570A (ja) 2016-12-01
EP2593483A2 (en) 2013-05-22
ES2425314R1 (es) 2014-07-09
FR2962655A1 (fr) 2012-01-20
NZ606775A (en) 2015-08-28
GB201302651D0 (en) 2013-04-03
MX2013000547A (es) 2014-04-14
ES2425314A2 (es) 2013-10-14
GB2495885A (en) 2013-04-24
MY165267A (en) 2018-03-15
SG187036A1 (en) 2013-02-28
US20130064860A1 (en) 2013-03-14
CN103282384A (zh) 2013-09-04
AU2011278042B2 (en) 2017-02-16
WO2012007849A3 (en) 2012-04-05
SG10201505564VA (en) 2015-09-29
JP2018150322A (ja) 2018-09-27
CA2805094A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
GB2495885A (en) Combination pharmaceutical composition and methods of treating genitourinary system disorders
CY1124311T1 (el) Παρεμποδιστες dna-pk
BR112012026801B8 (pt) conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2013010340A (es) Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
MX344009B (es) Conjugados de amatoxinas con enlaces mejorados.
MX2011008383A (es) Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll.
DK2331118T3 (da) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201100268A1 (ru) Вакцина
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
IN2012DN02471A (es)
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
MX2015002482A (es) Composicion inmunogenica.
DK2252322T3 (da) Vaccinesammensætninger
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MY158200A (en) Conjugates for the prevention of treatment of nicotine addiction
TR201902884T4 (tr) Mmp akti̇f vasküler bozucu ajanlar.

Legal Events

Date Code Title Description
FG Grant or registration